ArticleMolecular neurobiology2025
Exploring the Potential Mechanism of Action of Ursolic Acid for Parkinson's Disease: An Integrative Network Pharmacology, Docking and Molecular Dynamics Study.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling the Effects ofInternational journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease is the second-most prevalent neurological disease globally, affecting about 8.5 million people. Ursolic acid (UA) is a widely distributed pentacyclic triterpenoid compound with various health benefits, including anti-inflammatory, antioxidant, antiviral and anti-tumor properties. Although its anti-Parkinson's activity has been confirmed previously, related mechanisms and pathways of drug action have been studied limited. This study explored possible pathways and used network pharmacology to create a network map of drugs and disease targets. The ADMET profiling was performed to assess the suitability of UA prior to target identification. All the targets were collected and screened through database searches and literature mining. Targeted molecules data were entered into the Cytoscape platform to create a PPI network. Additionally, functional annotation analysis and pathway enrichment were performed. After screening 1520 PD targets and 27 ursolic acid targets, nine targets were identified as overlapping. Through bioinformatics annotation of these overlapping genes, a KEGG pathway gene ontology involving GO biological processes, cellular processes and molecular functions were obtained. From the results, it was observed that UA may exert its effects via the sphingolipid signaling pathway or by activating the cannabinoid receptor, both of which play significant roles in Parkinson's disease. These mechanisms were further supported by molecular docking and dynamics studies. Docking analysis revealed strong binding of UA to the selected target proteins, with ADAM10 exhibiting the highest binding affinity (- 8.4 kcal/mol), surpassing that of the native ligand, levodopa. To evaluate the stability and interaction profile, a 100-ns molecular dynamics simulation was conducted using MOE software, confirming the efficient binding of UA to the Parkinson's disease target ADAM10.
Indexed as
Identifiers
40551052What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.